News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
In the Media September 23, 2026
Branden Berns and Ryan Murr Discuss Reverse Mergers With Law360 Healthcare Authority
Partners Branden Berns and Ryan Murr were quoted in Law360 Healthcare Authority’s “As Stigma Fades, Reverse Mergers Boom in Biotech.”
Webcasts September 17, 2026
Webcast: Anticipating and Resolving Potential Licensing and Collaboration Disputes Before They Arise
Join Gibson Dunn lawyers for the first recorded session of a three-part series following a single life sciences collaboration and …
Publications September 16, 2026
Deal Trends — In Focus: Life Sciences
Our partners share insights on the trends shaping dealmaking in the Life Sciences sector—and what to watch in the months ahead.
Client Alert August 31, 2026
How ‘Most Favored Nation’ Regime Affects Biopharma Deals
This article describes the current state-of-play with MFN and key deal drafting considerations. Life sciences dealmaking is running at a …
Article August 27, 2026
Margaux Hall, Branden Berns, and Karen Spindler Have Authored Law360’s “How ‘Most Favored Nation’ Regime Affects Biopharma Deals”
Partners Margaux Hall, Branden Berns, and Karen Spindler have authored Law360’s “How 'Most Favored Nation' Regime Affects Biopharma Deals”
Publications August 6, 2026
Biopharma M&A: Mid-Cap Public-Target Market Survey (First-Half 2026)
In the first six months of 2026, acquirers announced 13 qualifying acquisitions of public biopharma targets worth $66.6 billion in upfront consideration.
Publications August 5, 2026
Contingent Value Rights: A Drafting Guide for Biopharma M&A
Contingent value rights have become a defining feature of biopharma M&A, appearing in under 10% of mid-cap public-target deals before 2019 but a quarter to a third of them in every year since 2023.
Client Alert August 3, 2026
California Supreme Court Holds That Drug Manufacturers Cannot Be Held Liable For Selling Nondefective Drugs On The Theory That They Should Have Made Safer Drugs Available Sooner
Gilead Tenofovir Cases, S283862 – Decided August 3, 2026 The California Supreme Court today rejected the theory that Gilead violated a …